Integra LifeSciences Reports Second Quarter 2026 Financial Results
Integra LifeSciences reported Q2 revenue of $418.8 million, up 0.8% year-over-year, with organic growth of 0.7%. Adjusted EPS increased to $0.56 from $0.45 in the prior year, driven by gross margin expansion to 61.3%. The company lowered its reported revenue guidance to $1.654 billion to $1.695 billion due to foreign exchange impacts but reaffirmed its full-year organic growth outlook of 0.8% to 3.3% and adjusted EPS guidance of $2.40 to $2.50. Operational milestones include the initiation of production at the Braintree facility to support the Q4 SurgiMend relaunch.
Key figures
- Eps
- 0.56
- Revenue
- $418.8 million
- Guidance
- FY26 Reported revenue $1.654B-$1.695B (lowered due to FX); Organic revenue growth 0.8%-3.3% (reaffirmed); Adjusted EPS $2.40-$2.50 (reaffirmed)
- Revenue Yoy
- 0.8%
- Net debt
- 1600000000
- Gross margin
- 61.3%
- Leverage ratio
- 4.1x
- Adjusted ebitda
- 78400000
- Organic revenue growth
- 0.7%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.